Low Vitamin D Levels Linked to Ulcerative Colitis Relapse

Low Vitamin D Levels Linked to Ulcerative Colitis Relapse

Gastroenterology April 3, 2017 at 9:10 AM 0 comments

CLINICAL relapse risk amongst individuals with ulcerative colitis (UC) more common if the levels of vitamin D in the blood are lower than required, according to researchers at the Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Senior author Dr Alan Moss, Digestive Disease Center, Beth Israel Deaconess Medical Center,Read More

Connection Uncovered Between Gut Bacteria and Patient Behaviour

Connection Uncovered Between Gut Bacteria and Patient Behaviour

Gastroenterology April 3, 2017 at 9:08 AM 0 comments

A POTENTIAL link has been discerned between gut bacteria and behaviour in patients with irritable bowel syndrome (IBS), a common gastrointestinal disorder with an approximate worldwide incidence of 11%. It is hoped that the findings from this study will assist in the development of new treatments; to date, treatment optionsRead More

Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

Hematology, Oncology March 28, 2017 at 2:48 PM 0 comments

Krakow, Poland / Berlin, Germany, March 28, 2017 – Selvita S.A. (WSE:SLV), and Berlin-Chemie Menarini, a company of the Menarini Group, announced today that both companies have entered into a global license agreement for SEL24, a dual PIM/FLT3 inhibitor currently in Phase I/II trials in acute myeloid leukemia (AML) patients. SEL24Read More

RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

Gastroenterology March 22, 2017 at 9:11 AM 0 comments

A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countries The open-label extension study (the MAP US2 study) is intended to assess the safety and efficacy of RHB-104 in patients whoRead More

Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

Hematology, Oncology March 17, 2017 at 11:44 AM 0 comments

Kraków, Poland, March 17, 2017 – Selvita (WSE:SLV),  a clinical stage drug discovery and development company focused on innovative medicines for patients with blood cancers, announced today that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML). SEL24 is a Selvita-developed first-in-classRead More

Genomic Health Unveils a Wealth of Data for the Oncotype DX® Breast Cancer Test, Reinforcing Its Value in Improving Patient Outcomes and Leading to More Cost-Effective Management

Oncology March 17, 2017 at 9:41 AM 0 comments

15 featured abstracts at the 15th St Gallen International Breast Cancer Conference underscore the growing adoption of the company’s cutting-edge genomic test to identify those patients who will benefit from chemotherapy after breast cancer surgery New real world evidence highlights the significant impact in reducing the burden of unnecessary chemotherapyRead More

Agena Bioscience Introduces New Lung and Colon Cancer Panels for Detection of Somatic Mutations from Liquid Biopsies and Solid Tumor Tissues

Gastroenterology, Oncology, Respiratory March 15, 2017 at 4:49 PM 0 comments

California, USA, March 15, 2017 – Agena Bioscience today introduced new targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSEEK™ Lung and Colon Panels enable detection of mutations as low as 0.1% minor allele frequency (MAF) from circulating tumor cells (CTCs) and circulatingRead More

Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval

Oncology March 14, 2017 at 12:11 PM 0 comments

Further Milestone Payment Under Novartis Collaboration as Kisqali® (ribociclib) Receives FDA approval as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor  Novartis drug Kisqali® (ribociclib, LEE011) receives marketing approval by the US FDA as a first-line drug for HR+/HER2- advanced breast cancer in combination with anRead More

Selvita to Present New Data from its Oncology Programs at the Upcoming AACR Annual Meeting 2017

Oncology March 13, 2017 at 2:23 PM 0 comments

Kraków, Poland, March 13, 2017 – Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the most recent data from its oncology programs at the upcoming AACR Annual Meeting 2017, which will place on April 1-5 2017, in Washington, DC, USA. DataRead More

German Community of Gynecological Oncology (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence

Oncology March 8, 2017 at 12:24 PM 0 comments

2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer Irvine, CA, USA and Amsterdam, the Netherlands, March 08, 2017 – Agendia, Inc., a world leader in personalized medicine and molecularRead More